Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.

@article{Ali2005RosiglitazoneCB,
  title={Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.},
  author={A Afshan Ali and Robert S. Weinstein and Scott A Stewart and A. Michael Parfitt and Stavros C Manolagas and Robert L. Jilka},
  journal={Endocrinology},
  year={2005},
  volume={146 3},
  pages={1226-35}
}
Because osteoblasts and marrow adipocytes are derived from a common mesenchymal progenitor, increased adipogenesis may occur at the expense of osteoblasts, leading to bone loss. Our previous in vitro studies indicated that activation of the proadipogenic transcription factor peroxisome proliferator-activated receptor isoform gamma 2 with rosiglitazone suppressed osteoblast differentiation. Here, we show that 5-month-old Swiss-Webster mice receiving rosiglitazone for 28 d exhibited bone loss… CONTINUE READING
158 Citations
54 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 158 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Similar Papers

Loading similar papers…